Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

Samaras P, Bargetzi M, Betticher DC, Driessen C, Duchosal MA, Heim D, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Schmidt A, Taverna C, Zander T, Renner C.

Swiss Med Wkly. 2019 Apr 3;149:w20031. doi: 10.4414/smw.2019.20031. eCollection 2019 Mar 25.

2.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, Salles GA, Witzig TE, Tilly H, Nowakowski GS.

J Clin Oncol. 2018 Jun 1;36(16):1603-1610. doi: 10.1200/JCO.2017.76.5198. Epub 2018 Apr 19.

3.

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.

Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, Maingonnat C, Mareschal S, Picquenot JM, Penther D, Jais JP, Tesson B, Peyrouze P, Figeac M, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Fabiani B, Delarue R, Peyrade F, André M, Ketterer N, Leroy K, Salles G, Molina TJ, Tilly H, Jardin F.

Clin Cancer Res. 2017 May 1;23(9):2232-2244. doi: 10.1158/1078-0432.CCR-16-1922. Epub 2016 Dec 6.

4.

Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).

Voegeli M, Rondeau S, Berardi Vilei S, Lerch E, Wannesson L, Pabst T, Rentschler J, Bargetzi M, Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M.

Hematol Oncol. 2017 Dec;35(4):576-583. doi: 10.1002/hon.2348. Epub 2016 Sep 28.

PMID:
27677906
5.

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.

Ghesquières H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G.

Hematol Oncol. 2017 Dec;35(4):447-455. doi: 10.1002/hon.2305. Epub 2016 Jun 10.

6.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.

Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, Legoff M, Biau D, Anract P, Roux C, Blanc-Autran E, Delarue R, Gisselbrecht C, Ketterer N, Recher C, Bonnet C, Peyrade F, Haioun C, Tilly H, Salles G, Brice P, Bouscary D, Deau B, Tamburini J.

Leuk Lymphoma. 2016 Dec;57(12):2820-2826. Epub 2016 Apr 27. Erratum in: Leuk Lymphoma. 2017 Feb;58(2):507-508.

7.

Can Low Dose Radiation Therapy (2 × 2 Gy) be Used in Primary Bilateral Conjunctival Follicular Lymphoma?

Cotting-Bodmer S, Moulin A, Herbort CP Jr, Ketterer N, Betz M, Pica A, Schalenbourg A.

Klin Monbl Augenheilkd. 2016 Apr;233(4):524-6. doi: 10.1055/s-0041-111824. Epub 2016 Apr 26. No abstract available.

8.

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.

Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, Maingonnat C, Jais JP, Peyrouze P, Figeac M, Molina TJ, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Salles G, Tilly H, Leroy K, Jardin F.

Clin Cancer Res. 2016 Jun 15;22(12):2919-28. doi: 10.1158/1078-0432.CCR-15-2305. Epub 2016 Jan 27.

9.

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.

Copie-Bergman C, Cuillière-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, Belhadj K, Fabiani B, Recher C, Petrella T, Ketterer N, Peyrade F, Haioun C, Nagel I, Siebert R, Jardin F, Leroy K, Jais JP, Tilly H, Molina TJ, Gaulard P.

Blood. 2015 Nov 26;126(22):2466-74. doi: 10.1182/blood-2015-05-647602. Epub 2015 Sep 15.

PMID:
26373676
10.

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C.

Bone Marrow Transplant. 2016 Jan;51(1):51-7. doi: 10.1038/bmt.2015.213. Epub 2015 Sep 14.

PMID:
26367239
11.

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

Samaras P, Bargetzi M, Betticher DC, Duchosal MA, Heim D, Hess U, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Taverna C, Zander T, Renner C.

Swiss Med Wkly. 2015 Feb 21;145:w14100. doi: 10.4414/smw.2015.14100. eCollection 2015. Review.

12.

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR.

J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18.

13.

High-dose therapy and autologous hematopoietic stem cell transplant in T-cell lymphoma: a single center experience.

Cairoli A, Ketterer N, Barelli S, Duchosal MA.

Leuk Lymphoma. 2014 Aug;55(8):1827-31. doi: 10.3109/10428194.2013.852666. Epub 2014 Feb 4.

PMID:
24138331
14.

Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?

Buchegger F, Mach JP, Press OW, Bischof Delaloye A, Larson SM, Prior JO, Ketterer N.

Ann Oncol. 2013 Jul;24(7):1948-9. doi: 10.1093/annonc/mdt198. Epub 2013 May 23. No abstract available.

15.

Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.

Jardin F, Delfau-Larue MH, Molina TJ, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Jais JP, Figeac M, Leroy K, Mareschal S, Salles GA, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Haioun C, Tilly H.

Leuk Lymphoma. 2013 Sep;54(9):1898-907. doi: 10.3109/10428194.2013.767456. Epub 2013 Feb 18.

PMID:
23327290
16.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).

Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C.

Ann Oncol. 2013 Apr;24(4):1032-7. doi: 10.1093/annonc/mds600. Epub 2012 Dec 12.

17.

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, Salles G, Moskowitz CH, Glass B.

J Clin Oncol. 2012 Dec 20;30(36):4462-9. doi: 10.1200/JCO.2012.41.9416. Epub 2012 Oct 22.

18.

Fertility preservation in cancer patients. Review of the French speaking part of Switzerland and recommendations for different situations.

Wunder D, Perey L; Réseau Romand Cancer et Fertilité, Achtari C, Ambrosetti A, Bellavia M, Delaloye JF, de Ziegler D, Gumy-Pause F, Helg C, Ketterer N, Petignat P, Primi MP, Rosselet-Christ A, Zaman K.

Swiss Med Wkly. 2012 Oct 1;142:w13645. doi: 10.4414/smw.2012.13645. eCollection 2012. Review.

19.

Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab radioimmunotherapy may correlate with better tolerance.

Buchegger F, Prior JO, Allenbach G, Baechler S, Kosinski M, Helg C, Chalandon Y, Ratib O, Delaloye AB, Ketterer N.

Clin Nucl Med. 2012 Oct;37(10):960-4. doi: 10.1097/RLU.0b013e318251e3af.

PMID:
22955069
20.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G.

J Clin Oncol. 2012 Jul 10;30(20):2475-82. doi: 10.1200/JCO.2011.37.4918. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. J Clin Oncol. 2014 Apr 20;32(12):1285.

PMID:
22585692
21.

An unusual uterine tumor with signet ring cell features.

Sarro R, Fiche M, Bisig B, Ketterer N, Benhattar J, Achtari C, de Leval L.

Int J Gynecol Pathol. 2012 May;31(3):236-41. doi: 10.1097/PGP.0b013e31823b6f6a.

PMID:
22498940
22.

A Brownian ratchet for protein translocation including dissociation of ratcheting sites.

Depperschmidt A, Ketterer N, Pfaffelhuber P.

J Math Biol. 2013 Feb;66(3):505-34. doi: 10.1007/s00285-012-0519-8. Epub 2012 Feb 22.

PMID:
22354539
23.

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.

Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich PY, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Trojan A, Bouabdallah K, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N; Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network.

Haematologica. 2012 Jul;97(7):1085-91. doi: 10.3324/haematol.2011.053173. Epub 2012 Feb 7.

24.

Acute coronary syndrome upon receiving carmustine infusion before autologous stem-cell transplantation.

Waibel Pachinger C, Rosselet A, Berthouzoz S, Luthi F, Ketterer N.

Hematol Oncol. 2012 Dec;30(4):216-8. doi: 10.1002/hon.1028. Epub 2012 Jan 27. No abstract available.

PMID:
22287477
25.

Diagnosis and treatment of follicular lymphoma.

Hitz F, Ketterer N, Lohri A, Mey U, Pederiva S, Renner C, Taverna C, Hartmann A, Yeow K, Bodis S, Zucca E.

Swiss Med Wkly. 2011 Aug 4;141:w13247. doi: 10.4414/smw.2011.13247. eCollection 2011. Review.

26.

Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.

Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Delaloye AB, Press OW, Ketterer N.

J Nucl Med. 2011 Jun;52(6):896-900. doi: 10.2967/jnumed.111.087460. Epub 2011 May 13.

27.

Home care--a safe and attractive alternative to inpatient administration of intensive chemotherapies.

Lüthi F, Fucina N, Divorne N, Santos-Eggimann B, Currat-Zweifel C, Rollier P, Wasserfallen JB, Ketterer N, Leyvraz S.

Support Care Cancer. 2012 Mar;20(3):575-81. doi: 10.1007/s00520-011-1125-9. Epub 2011 Mar 8.

PMID:
21384139
28.

Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.

Provencher S, Ferlay C, Alaoui-Slimani K, Devidas A, Lepretre S, de Prijck B, Sebban C, de la Fouchardiere A, Chassagne-Clement C, Ketterer N, Thyss A, Delannoy A, Tilly H, Biron P, Blay JY, Ghesquières H.

Hematol Oncol. 2011 Mar;29(1):10-6. doi: 10.1002/hon.944.

PMID:
21381074
30.

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.

Moreau P, Attal M, Pégourié B, Planche L, Hulin C, Facon T, Stoppa AM, Fuzibet JG, Grosbois B, Doyen C, Ketterer N, Sebban C, Kolb B, Chaleteix C, Dib M, Voillat L, Fontan J, Garderet L, Jaubert J, Mathiot C, Esseltine D, Avet-Loiseau H, Harousseau JL; IFM 2005-01 study investigators.

Blood. 2011 Mar 17;117(11):3041-4. doi: 10.1182/blood-2010-08-300863. Epub 2010 Nov 23. Erratum in: Blood. 2012 Nov 15;120(20):4274.

PMID:
21098740
31.

Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.

Cicone F, Russo E, Carpaneto A, Prior JO, Delaloye AB, Scopinaro F, Ketterer N.

Hematol Oncol. 2011 Sep;29(3):131-8. doi: 10.1002/hon.968. Epub 2010 Sep 22.

PMID:
20862654
32.

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N.

J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896.

33.

Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.

Taverna C, Bargetzi M, Betticher D, Gmür J, Gregor M, Heim D, Hess U, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Renner C.

Swiss Med Wkly. 2010 Sep 13;140:w13054. doi: 10.4414/smw.2010.13054. eCollection 2010. Review.

34.

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L.

J Clin Oncol. 2010 Apr 20;28(12):2085-93. doi: 10.1200/JCO.2009.25.1900. Epub 2010 Mar 22.

PMID:
20308665
35.

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.

Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE.

Br J Haematol. 2010 Jun;149(6):907-10. doi: 10.1111/j.1365-2141.2010.08134.x. Epub 2010 Mar 1. No abstract available.

PMID:
20201944
36.

Current multiple myeloma treatment strategies with novel agents: a European perspective.

Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S.

Oncologist. 2010;15(1):6-25. doi: 10.1634/theoncologist.2009-0203. Epub 2010 Jan 19. Review.

37.

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.

Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P.

J Clin Oncol. 2009 Dec 1;27(34):5720-6. doi: 10.1200/JCO.2008.21.1060. Epub 2009 Oct 13.

PMID:
19826130
38.

[Management of lymphoma and pregnancy].

Schusterbauer C, Cairoli A, Ketterer N.

Rev Med Suisse. 2009 May 20;5(204):1104-6, 1108-9. French.

PMID:
19580207
39.

Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.

Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.

Ann Hematol. 2009 Jul;88(7):681-5. doi: 10.1007/s00277-008-0652-z. Epub 2008 Dec 6.

PMID:
19066891
40.

Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.

Buchegger F, Press OW, Delaloye AB, Ketterer N.

Oncologist. 2008 Jun;13(6):657-67. doi: 10.1634/theoncologist.2008-0020. Review.

41.

Pi*-pi* bonding interactions generated by halogen oxidation of zirconium(IV) redox-active ligand complexes.

Ketterer NA, Fan H, Blackmore KJ, Yang X, Ziller JW, Baik MH, Heyduk AF.

J Am Chem Soc. 2008 Apr 2;130(13):4364-74. doi: 10.1021/ja077337m. Epub 2008 Mar 11.

PMID:
18331029
42.

[Radioimmunotherapy of follicular lymphoma: a step towards cure?].

Ketterer N, Bischof Delaloye A, Helg C, Luthi F, Buchegger F.

Bull Cancer. 2007 Sep;94(9):799-806. Review. French.

43.

[Overview on cancer in young adults].

Nay C, Luthi F, Ketterer N, Bauer J, Leyvraz S.

Rev Med Suisse. 2007 May 23;3(112):1305-6, 1308-10. Review. French.

PMID:
17596066
44.

Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma.

Wavre A, Baur AS, Betz M, Mühlematter D, Jotterand M, Zaman K, Ketterer N.

Neuro Oncol. 2007 Jul;9(3):370-2. Epub 2007 May 23.

45.

[Multiple myeloma].

Rosselet A, Ketterer N.

Rev Med Suisse. 2007 Mar 14;3(102):695-700. Review. French. No abstract available.

PMID:
17444205
46.

Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.

Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, Kosinski M, Mach JP, Ketterer N.

Br J Cancer. 2006 Jun 19;94(12):1770-6. Epub 2006 May 9.

47.

High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults.

Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, Champion KM, Secondino S, Selle F, Ketterer N, Grignani G, Siena S, Demirer T; European Group for Blood and Marrow Transplantation (EBMT) Solid Tumors Working Party.

Ann Oncol. 2006 Oct;17(10):1479-88. Epub 2006 Mar 17. Review.

PMID:
16547069
48.

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P.

Blood. 2006 May 1;107(9):3474-80. Epub 2006 Jan 5.

PMID:
16397129
49.

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.

Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto JJ, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome group.

Blood. 2006 Jan 1;107(1):397-403. Epub 2005 Sep 6.

PMID:
16144800
50.

Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literature.

George AC, Ozsahin M, Janzer R, Agassis S, Meuli R, Baur AS, Frossard V, Leyvraz S, Ketterer N.

Bull Cancer. 2005 Jul;92(7):E51-6.

Supplemental Content

Loading ...
Support Center